Latest News

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 annual meeting, Dr. Alexander Kretschmer presented data assessing salvage therapies for PSMA PET/CT-positive node-only recurrent prostate cancer. The role of salvage lymph node dissection in the management of nodal-only recurrent prostate cancer remains controversial. While unfavorable long-term oncological outcomes have cast doubt […]

(UroToday.com) In this point-counterpoint session, Dr. Sigrid Carlsson and Dr. Grégoire Robert debate the topic of active surveillance (AS) for the International Society of Urological Pathology (ISUP) Grade Group 2 (GG2) prostate cancer. Dr. Carlson argues for active surveillance while Dr. Robert argues against it.

(UroToday.com) In the Guideline Session II: Prostate Cancer: cN+ in newly diagnosed patients during the 2021 European Association of Urology meeting, Maria De Santis argues the point of view that more than ADT is required as systemic therapy for patients with clinically node-positive prostate cancer. She notes the challenges of this argument as there is little […]

(UroToday.com) In this final talk from the thematic session at the 2021 European Association of Urology (EAU) annual meeting, focusing on immunotherapy for urothelial cancer, Dr. Matthew Galsky takes a look at the future – and discusses the ideal combination therapies.

(UroToday.com) At the 2021 European Association of Urology annual meeting’s metastatic prostate cancer session, Dr. Yakup Kordan and colleagues presented results of their study assessing the impact of Ga-68 PSMA PET or nomograms for preoperative prediction of lymph node invasion in prostate cancer. Previously, the Briganti 20121, Briganti 20182, and Partin nomograms have been published and […]

(UroToday.com) The European Association of Urology 2021 Annual Meeting’s Game-Changing session included a presentation by Professor Johann De Bono discussing the VISION trial, a phase 3 study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). As PSMA is highly expressed in prostate cancer and mCRPC lesions, the combination of PSMA-617 with the beta-emitter lutetium […]

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 annual meeting, Dr. Lorenzo Bianchi discussed the external validation of a nomogram for predicting 68Ga-PSMA PET/CT detection rate in patients with prostate cancer recurrence. PSMA functional imaging has proven to have a significant clinical impact in re-staging prostate cancer patients, however, a […]

(UroToday.com) The 2021 European Association of Urology (EAU) annual meeting had a Controversies in Bladder Cancer 2021: Rapid-fire debates session. The session was introduced by Dr. Ashish Kamat with chairs of the session, Professors Joan Palou and Arnulf Stenzl. There were five rapid-fire debates with case-based discussions, multiple presenters have the opportunity to discuss nuances of common […]

(UroToday.com) The first talk of this game-changing session at the 2021 European Association of Urology (EAU) annual meeting, Dr. Nick Beije of Rotterdam, presented the final results of the CirGuidance Study, which focused on the use of the circulating tumor cells (CTCs) to drive neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). This was followed by a […]

(UroToday.com) In this session at the 2021 European Association of Urology (EAU) virtual annual meeting, Prof. Dr. Jürgen E. Gschwend from Munich, Germany presents data from the IMvigor010 study, specifically an analysis of ctDNA tested patients and their outcomes. Prof. Dr. Arnulf Stenzl follows this up with a discussion of the data and provides clinical context. Dr. […]